Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T.

Nature. 2019 May;569(7754):131-135. doi: 10.1038/s41586-019-1130-6. Epub 2019 Apr 17.

PMID:
30996350
2.
3.

Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.

Duan W, Chen K, Jiang Z, Chen X, Sun L, Li J, Lei J, Xu Q, Ma J, Li X, Han L, Wang Z, Wu Z, Wang F, Wu E, Ma Q, Ma Z.

Cancer Lett. 2017 Jan 28;385:225-233. doi: 10.1016/j.canlet.2016.10.019. Epub 2016 Oct 20.

PMID:
27773749
4.

Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.

Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S.

Gastroenterology. 2018 Apr;154(5):1524-1537.e6. doi: 10.1053/j.gastro.2017.12.014. Epub 2017 Dec 21.

PMID:
29274868
5.

Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.

Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR.

Eur J Cancer. 2014 Oct;50(15):2570-82. doi: 10.1016/j.ejca.2014.06.021. Epub 2014 Aug 1. Review.

PMID:
25091797
6.

LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker.

Bressy C, Lac S, Nigri J, Leca J, Roques J, Lavaut MN, Secq V, Guillaumond F, Bui TT, Pietrasz D, Granjeaud S, Bachet JB, Ouaissi M, Iovanna J, Vasseur S, Tomasini R.

Cancer Res. 2018 Feb 15;78(4):909-921. doi: 10.1158/0008-5472.CAN-15-2790. Epub 2017 Dec 21.

7.

Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.

Gastroenterology. 2015 Dec;149(7):1932-1943.e9. doi: 10.1053/j.gastro.2015.07.058. Epub 2015 Aug 7.

8.

Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.

Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D, Jain RK.

Cancer Discov. 2016 Aug;6(8):852-69. doi: 10.1158/2159-8290.CD-15-1177. Epub 2016 May 31.

9.

Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.

Chen L, Xu X, Wen X, Xu S, Wang L, Lu W, Jiang M, Huang J, Yang D, Wang J, Zheng M, Zhou XZ, Lu KP, Liu H.

Cancer Sci. 2019 Aug;110(8):2442-2455. doi: 10.1111/cas.14085. Epub 2019 Jun 25.

10.

Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.

Incio J, Suboj P, Chin SM, Vardam-Kaur T, Liu H, Hato T, Babykutty S, Chen I, Deshpande V, Jain RK, Fukumura D.

PLoS One. 2015 Dec 7;10(12):e0141392. doi: 10.1371/journal.pone.0141392. eCollection 2015.

11.

Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.

Wu YS, Chung I, Wong WF, Masamune A, Sim MS, Looi CY.

Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):296-306. doi: 10.1016/j.bbagen.2016.10.006. Epub 2016 Oct 14.

PMID:
27750041
12.

Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.

Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM.

Gastroenterology. 2011 Oct;141(4):1486-97, 1497.e1-14. doi: 10.1053/j.gastro.2011.06.047. Epub 2011 Jun 24.

PMID:
21704588
13.

Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.

Jiang Z, Zhou C, Cheng L, Yan B, Chen K, Chen X, Zong L, Lei J, Duan W, Xu Q, Li X, Wang Z, Ma Q, Ma J.

J Exp Clin Cancer Res. 2018 Mar 27;37(1):69. doi: 10.1186/s13046-018-0740-4.

14.

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R.

Nature. 2015 Nov 26;527(7579):525-530. doi: 10.1038/nature16064. Epub 2015 Nov 11.

15.

Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.

Zhao X, Fan W, Xu Z, Chen H, He Y, Yang G, Yang G, Hu H, Tang S, Wang P, Zhang Z, Xu P, Yu M.

Oncotarget. 2016 Dec 6;7(49):81110-81122. doi: 10.18632/oncotarget.13212.

16.

Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.

Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L.

Tumour Biol. 2016 Nov;37(11):15283-15291. Epub 2016 Sep 30.

PMID:
27696296
17.

Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells.

Nagathihalli NS, Castellanos JA, VanSaun MN, Dai X, Ambrose M, Guo Q, Xiong Y, Merchant NB.

Oncotarget. 2016 Oct 4;7(40):65982-65992. doi: 10.18632/oncotarget.11786.

18.

Generation of an in vitro 3D PDAC stroma rich spheroid model.

Ware MJ, Keshishian V, Law JJ, Ho JC, Favela CA, Rees P, Smith B, Mohammad S, Hwang RF, Rajapakshe K, Coarfa C, Huang S, Edwards DP, Corr SJ, Godin B, Curley SA.

Biomaterials. 2016 Nov;108:129-42. doi: 10.1016/j.biomaterials.2016.08.041. Epub 2016 Sep 2.

19.

Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.

Ma Y, Hwang RF, Logsdon CD, Ullrich SE.

Cancer Res. 2013 Jul 1;73(13):3927-37. doi: 10.1158/0008-5472.CAN-12-4479. Epub 2013 Apr 30.

20.

[Expression and significance of leukemia inhibitory factor in human pancreatic cancer].

Peng F, Zhou J, Sheng W, Zhang D, Dong M.

Zhonghua Yi Xue Za Zhi. 2014 Jan 14;94(2):90-5. Chinese.

PMID:
24721346

Supplemental Content

Support Center